Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
| 2.39 Delayed Data As of Aug 12 |  +0.14 / +6.22%Today’s Change | 1.26 Today|||52-Week Range 6.86 | -36.27% Year-to-Date |
Latest ADAP News | Press Releases
No recent news for Adaptimmune Therapeutics PLC.
Today’s Trading
| Previous close | 2.25 |
| Today’s open | 2.35 |
| Day’s range | 2.35 - 2.53 |
| Volume | 40,381 |
| Average volume (3 months) | 473,292 |
| Market cap | $401.9M |
Data as of 3:59pm ET, 08/12/2022
Growth & Valuation
| Earnings growth (last year) | -10.25% |
| Earnings growth (this year) | -583.82% |
| Earnings growth (next 5 years) | +5.60% |
| Revenue growth (last year) | +54.14% |
| P/E ratio | NM |
| Price/Sales | 95.03 |
| Price/Book | 1.87 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XXII22nd Century Group I... | +0.01 | +0.83% |
| ---- | ||
| SELBSelecta Biosciences ... | 0.00 | 0.00% |
| TCRTAlaunos Therapeutics... | -0.13 | -7.02% |
Data as of 4:00pm ET, 08/12/2022
Financials
| Next reporting date | November 9, 2022 |
| EPS forecast (this quarter) | -$0.29 |
| Annual revenue (last year) | $6.1M |
| Annual profit (last year) | -$158.1M |
| Net profit margin | -2,570.99% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Abingdon, Oxfordshire |
Forecasts
